|
#1
07.05.2005, 09:33
|
|||
|
|||
|
Îíêîëîãèÿ
Îíêîëîãèÿ
Ïðîñüáà ïðèâîäèòü êðàòêîå îïèñàíèå ðåñóðñîâ 
|
|
#2
10.05.2005, 14:35
|
||||
|
||||
|
Ïîäáîðêà ãàéäëàéíîâ ïî ëå÷åíèþ îíêîïàòîëîãèè (âêëþ÷àÿ è îíêîãåìàòîëîãèþ) îò NCCN Clinical Practice Guidelines in Oncology (ÏÄÔ-ïðåçåíòàöèè)
Guidelines for Treatment of Cancer by Site Guidelines for Detection, Prevention and Risk Reduction Guidelines for Supportive Care [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#3
24.05.2005, 19:00
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
The Swedish Council on Technology Assessment in Health Care Manual Lymph Drainage Combined With Compression Therapy for Arm Lymphedema Following Breast Cancer Treatment Aromatase Inhibitors in Breast CancerComputed tomography in screening for lung cancer Tumor vaccination Radiotherapy for cancer BNCT - Radiotherapy with neutrons for brain tumors Stem cell transplantation for metastasized kidney cancer Trastuzumab (herceptin) for metastasized breast cancer Photodynamic therapy for skin cancer Human papillomavirus testing in primary cervical cancer screening Screening for colorectal cancer Screening for colorectal cancer
|
|
#4
28.05.2005, 19:15
|
||||
|
||||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#5
02.06.2005, 16:25
|
||||
|
||||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ñàéò Kidney Cancer Association. The organization of patients, families, doctors, and health professionals involved in kidney cancer.
|
|
#6
07.06.2005, 19:54
|
|||
|
|||
|
Memorial Sloan-Kettering Cancer Center (îäèí èç ñàìûõ ïðåñòèæíûõ è óñïåøíûõ íàó÷íûõ èíñòèòóòîâ ÑØÀ, îäèí èç êðóïíåéøèõ ìèðîâûõ öåíòðîâ ïî èçó÷åíèþ ðàêà.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ðåñóðñû äëÿ ñïåöèàëèñòîâ è ïàöèåíòîâ ïî ëå÷åíèþ, äèàãíîñòèêå è îáó÷åíèþ â îáëàñòè îíêîëîãèè. Àëôàâèòíûé óêàçàòåëü "àëüòåðíàòèâíûõ ìåòîäîâ". [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] CA: a cancer journal for clinicians oïóáëèêîâàë öåëóþ ñåðèþ îáçîðîâ ïî ñîìíèòåëüíûì ìåòîäàì ëå÷åíèÿ. Îñîáåííî èíòåðåñíî ÷èòàòü êàê çàðîæäàëñÿ òîò èëè èíîé ìåòîä è êòî çà íèì ñòîÿë... îòïàäàþò âñÿêèå ñîìíåíèÿ... Questionable methods of cancer management: electronic devices. CA Cancer J Clin. 1994 Mar-Apr;44(2):115-27. Review. Questionable methods of cancer management: 'nutritional' therapies. CA Cancer J Clin. 1993 Sep-Oct;43(5):309-19. Review. Questionable methods of cancer management: the Committee for Freedom of Choice in Medicine, Inc. CA Cancer J Clin. 1993 Mar-Apr;43(2):117-23. Questionable methods of cancer management: Cancell/Entelev. CA Cancer J Clin. 1993 Jan-Feb;43(1):57-62. Questionable methods of cancer management: hydrogen peroxide and other 'hyperoxygenation' therapies. CA Cancer J Clin. 1993 Jan-Feb;43(1):47-56. Questionable methods of cancer management. Immuno-augmentative therapy (IAT). CA Cancer J Clin. 1991 Nov-Dec;41(6):357-64. __________________ E.E. Ñòóäåíöîâ Albert Einstein College of Medicine ×àñòè÷íûé ïåðåâîä íåêîòîðûõ ðåñóðñîâ http://www.forums.rusmedserv.com/sho...28&postcount=6
|
|
#7
15.06.2005, 17:30
|
|||
|
|||
|
Îíêîëîãè÷åñêèé öåíòð óíèâåðñèòåòà Ïåíñèëüâàíèè
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
|
|
#9
12.07.2005, 14:05
|
||||
|
||||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Cancer Care Ontario is a planning and research organization that advises the Ontario government on all aspects of provincial cancer care, provides information to health care providers and decision-makers, and motivates better cancer system performance.
|
|
#11
10.06.2006, 15:41
|
||||
|
||||
|
International information resource on breast cancer treatment intended for healthcare professionals, patients and carers.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
|
#12
12.07.2006, 14:06
|
|||
|
|||
|
Êëèíè÷åñêèå Ðóêîâîäñòâà
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer London (UK): National Institute for Clinical Excellence (NICE); 2003 May [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Adjuvant radiotherapy in women with stage I endometrial cancer: a clinical practice guideline Gynecology Cancer Disease Site Group. Toronto (ON): 2006 Mar 9. (Evidence-based series). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Imatinib mesylate (Gleevec™) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours: a clinical practice guideline. Sarcoma Disease Site Group.(ON): Cancer Care Ontario (CCO); 2006 Apr 6. (Evidence-based series). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Radiotherapy for newly diagnosed malignant glioma in adults: a clinical practice guideline Neuro-Oncology Disease Site Group. Toronto (ON): Cancer Care Ontario (CCO); 2005 (Evidence-based series). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a clinical practice guideline Lung Cancer Disease Site Group. Toronto (ON): Cancer Care Ontario (CCO); 2006 Mar (Evidence-based series). [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] The role of cytoreductive nephrectomy in metastatic renal cell cancer: a clinical practice guideline Genitourinary Cancer Disease Site Group. Toronto (ON): Cancer Care Ontario (CCO); 2006 (Evidence-based series).
|
|
#13
29.09.2006, 08:02
|
|||
|
|||
|
open access journal
Infectious Agents and Cancer [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] This journal considers articles on all aspects of basic, clinical and translational research that provide an insight into the association between chronic infections and cancer.
|
|
#14
09.02.2007, 20:53
|
|||
|
|||
|
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Managing central venous access devices in cancer patients: a clinical practice guideline. Central Venous Access Device Guideline Panel.
|
|
#15
28.02.2007, 10:21
|
|||
|
|||
|
Æóðíàë "Îöåíêà ìåäèöèíñêèõ òåõíîëîãèé"
ïîëíûé òåêñò pdf [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Health Technol Assess. 2007 Jan;11(2):1-198. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R. Centre for Reviews and Dissemination, University of York, UK. OBJECTIVES: A systematic review was undertaken and an economic model constructed to evaluate the clinical effectiveness and cost-effectiveness of docetaxel (Taxotere(R), Sanofi-Aventis) in combination with prednisone/prednisolone for the treatment of metastatic hormone-refractory prostate cancer (mHRPC). The main comparators considered were other established chemotherapy regimens and best supportive care. DATA SOURCES: Twenty-one resources (including MEDLINE, EMBASE and the Cochrane Library) were searched to April 2005. REVIEW METHODS: Two reviewers independently assessed studies for inclusion. Data from included studies were extracted and quality assessed. Where appropriate, outcomes were synthesised using formal analytic approaches. A new economic model was developed in order to establish the cost-effectiveness of docetaxel compared with a range of potential comparators. A separate review was undertaken to identify sources of utility data required to estimate quality-adjusted life-years (QALYs). Sensitivity analyses were also undertaken to explore the robustness of the main analysis to alternative assumptions related to quality of life. Monte Carlo simulation was used to propagate uncertainty in input parameters through the model in such a way that the results of the analysis could be presented with their uncertainty. The impact of uncertainty surrounding the decision was established using value of information and implementation approaches. RESULTS: Seven randomised controlled trials were identified that met the inclusion criteria. A direct comparison of docetaxel plus prednisone versus mitoxantrone plus prednisone in an open-label randomised trial showed improved outcomes for docetaxel plus prednisone in terms of overall survival, quality of life, pain and prostate-specific antigen decline. Two other chemotherapy regimens that included docetaxel: docetaxel plus estramustine and docetaxel plus prednisone plus estramustine, also showed improved outcomes in comparison with mitoxantrone plus prednisone. Indirect comparison suggested that docetaxel plus prednisone seems to be superior to corticosteroids alone in terms of overall survival. Conclusions on cost-effectiveness were primarily informed by the results of the in-house model. This indicated that mitoxantrone plus a corticosteroid is probably cheaper and more effective than corticosteroid alone. Compared with mitoxantrone plus prednisone/prednisolone, the use of docetaxel plus prednisone/prednisolone (3-weekly) appears cost-effective only if the NHS is prepared to pay pound33,000 per QALY. The incremental cost-effectiveness ratio associated with docetaxel plus prednisone (3-weekly) remained fairly robust to these variations with estimates ranging from pound 28,000 to pound 33,000 per QALY. Value of information analysis revealed that further research is potentially valuable. Given a maximum acceptable ratio of pound30,000 per QALY, the expected value of information was estimated to be approximately pound13 million. CONCLUSIONS: This systematic review of the research suggests that docetaxel plus prednisone seems to be the most effective treatment for men with mHRPC. The economic model suggests that treatment with docetaxel plus prednisone/prednisolone is cost-effective in patients with mHRPC provided the NHS is prepared to pay pound33,000 per additional QALY. Future research should include the direct assessment of quality of life and utility gain associated with different treatments, including the effect of adverse events of treatment, using generic instruments, which are suitable for the purposes of cost-effectiveness analyses.
|
Ëèíåéíûé âèä
